Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Bert Tomson"'
Autor:
Judith A.E. Somers, Bert Tomson, Marian G.J. van Kraaij, Claudia M Weller, Johanna G van der Bon, Geert W. Haasnoot, Aukje L. Kreuger
Publikováno v:
Transfusion
textabstractBACKGROUND: Patients refractory for platelet transfusions benefit from human leukocyte antigen (HLA)-matched platelet transfusions. Differences in ethnic background of patients and donors could hamper the availability of sufficient number
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72b617d3fea2ba287a57968bfa021ae7
http://europepmc.org/articles/PMC7317777
http://europepmc.org/articles/PMC7317777
Autor:
Johanna G. van der Bom, Anja B. U. Makelburg, Leo M.G. van de Watering, Aukje L. Kreuger, Judith A.E. Somers, Claudia M Weller, Marian G.J. van Kraaij, Bert Tomson
Publikováno v:
Transfusion. Wiley
Transfusion, 59(11), 3303-3307. WILEY
Transfusion, 59(11), 3303-3307. WILEY
BACKGROUND Recipients of platelet transfusions with 1-hour corrected count increments (1hCCIs) of 7.5 or less on two subsequent platelet transfusions with random platelets may benefit from human leukocyte antigen (HLA)-matched platelet concentrates.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70eb408dceee0df346b9867a9ac49e28
https://hdl.handle.net/11370/811c317b-070d-456d-883a-1a2cb9a2cf6c
https://hdl.handle.net/11370/811c317b-070d-456d-883a-1a2cb9a2cf6c
Autor:
Anja ten Brinke, Anno Saris, John Scharenberg, S. Marieke van Ham, Arend Mulder, Jos Lorinser, Anneke Brand, Pieter F. van der Meer, Jaap Jan Zwaginga, Frans H.J. Claas, Bert Tomson
Publikováno v:
Blood, 131(1), 144-152. American Society of Hematology
Blood, 131(1), 144-152
Blood, 131(1), 144-152. AMER SOC HEMATOLOGY
Blood, 131(1), 144-152
Blood, 131(1), 144-152. AMER SOC HEMATOLOGY
Patients refractory to platelet transfusions because of alloimmunization require HLA-matched platelets, which is only possible if a large HLA-typed donor pool is available. However, even then, patients with broad immunization or rare haplotypes may n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61d05473572ec6138652c0777c6a066c
https://pubmed.ncbi.nlm.nih.gov/29301774
https://pubmed.ncbi.nlm.nih.gov/29301774
Autor:
Bert Tomson, Dirk de Korte, Guido Kruit, Geert A H Peeters, Ido J. Bontekoe, Pieter F. van der Meer, Pleun J. van Toledo
Publikováno v:
Transfusion. 52:819-827
BACKGROUND: Plasma can be removed from platelet (PLT) concentrates (PCs) when volume reduction for PLT transfusion is indicated. Volume-reduced PCs are currently produced from pooled buffy coat (BC) PCs or apheresis PCs by pretransfusion volume reduc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02006ca5a324a926db834028de1f4435
https://doi.org/10.1111/j.1537-2995.2011.03357.x
https://doi.org/10.1111/j.1537-2995.2011.03357.x
Publikováno v:
Transfusion. 52:742-751
BACKGROUND: Our blood bank prepares, on indication or request, a volume-reduced (VR) platelet (PLT) product with greater than 95% reduced plasma content and a 15-fold higher PLT concentration, potentially minimizing adverse reactions due to plasma, i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df39369e350c60161c061ce1aa18463c
https://doi.org/10.1111/j.1537-2995.2011.03364.x
https://doi.org/10.1111/j.1537-2995.2011.03364.x
Publikováno v:
Transfusion. 52(4)
Our blood bank prepares, on indication or request, a volume-reduced (VR) platelet (PLT) product with greater than 95% reduced plasma content and a 15-fold higher PLT concentration, potentially minimizing adverse reactions due to plasma, in particular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5b2ce94c8c3700b6668d4563fd917132
https://pubmed.ncbi.nlm.nih.gov/21981629
https://pubmed.ncbi.nlm.nih.gov/21981629
Autor:
Pieter F, van der Meer, Ido J, Bontekoe, Guido, Kruit, Geert, Peeters, Pleun J, van Toledo, Bert, Tomson, Dirk, de Korte
Publikováno v:
Transfusion. 52(4)
Plasma can be removed from platelet (PLT) concentrates (PCs) when volume reduction for PLT transfusion is indicated. Volume-reduced PCs are currently produced from pooled buffy coat (BC) PCs or apheresis PCs by pretransfusion volume reduction, follow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4be5b89679ac23f172c6f9f8f3fcb6f3
https://pubmed.ncbi.nlm.nih.gov/21981439
https://pubmed.ncbi.nlm.nih.gov/21981439
Publikováno v:
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 42(1)
The measurement of recovery and survival of platelets is an important decisive factor when ‘new’ platelet products have been developed. Recovery and survival measurements are mostly performed with radioactive-labeled platelets in healthy voluntee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4f6a5f079aaf3ee4e33df009938b1b6
https://pubmed.ncbi.nlm.nih.gov/19931490
https://pubmed.ncbi.nlm.nih.gov/19931490
Publikováno v:
Human Immunology, 67, 6, pp. 413-8
Human Immunology, 67, 413-8
Human Immunology, 67, 413-8
Item does not contain fulltext Platelet transfusions are indispensable for supportive care of patients with hematological diseases. We describe the developments in platelet products for transfusion since the 1970s, when, in particular, support for pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fd725f6341d8214a7633d444de325cf
https://hdl.handle.net/2066/49702
https://hdl.handle.net/2066/49702
